Brief: Nykode Therapeutics Announces New Interim Data From Vb-C-03 Trial
Feb 24 (Reuters) - Nykode Therapeutics ASA NYKD.OL: ANNOUNCES NEW INTERIM DATA FROM THE VB-C-03 TRIAL SHOWING ENCOURAGING ANTI-TUMOR ACTIVITY AND TOLERABILITY OF ABI-SUVA (VB10.16) ANTI-TUMOR ACTIVITY OBSERVED WITH ORR OF 38.5% Source text: ID:nObipvZrVa Further company coverage: NYKD.OL (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Nykode Therapeutics ASA
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Nykode Therapeutics Mulls Private Placement
Brief: Nykode Receives Draft Recommendation In Tax Case
Brief: Nykode Therapeutics Receives U.S. Vaccine Patent
Brief: Nykode Therapeutics Expects Draft Recommendation From Norwegian Tax Appeal Board In August 2026